Patent application number | Description | Published |
20080247885 | West Compression Apparatus and Method - This wet compression invention with a vaporizable fluid mist demonstrates major performance improvements over the relevant art in achieving a high degree of saturation, providing sensible cooling, strongly reducing the temperature increase due to compression work, reducing excess diluent air flow for downstream combustion, reducing compression noise, and increasing the achievable compressor pressure ratio?. These improvements are obtained by one or more of: high mist or overspray from a) progressive axial injection of vaporizable fluid along the streamwise compression flow path, and b) transverse vaporizable fluid delivery from stators, rotors, perforated tubes, and/or duct walls, matching the gaseous fluid flow distribution across the compressor stream; c) reducing the compressor cross-sectional flow area of downstream compressor stages relative to up-stream stages, and d) increasing the rate of downstream vaporizable fluid injection relative to the rate of upstream injection, as a function of each compressor stage pressure ratio. | 10-09-2008 |
20090028645 | THERMOGENERATOR TO REMEDIATE CONTAMINATED SITES - A remediation system and method for decontaminating a polluted site. An outlet system is to deliver a remediation fluid to the polluted site, and an inlet system receives a contaminated effluent from the polluted site. A processing system extracts a contaminant component from the contaminated effluent. A reactor receives the extracted contaminant component as a first reactant, and also, a second reactant. The reactor generates a reaction product-containing exit fluid stream, a controlled portion of which is released from the system. The remaining portion of the reactor exit fluid forms the remediation fluid. Optionally, the remaining portion is combined with a controlled quantity of the second reactant to form the remediation fluid. In addition, a controlled quantity of diluent/coolant fluid may be delivered into a reaction process in the reactor and/or downstream of the reaction process, and/or separately in a heat transfer system. This cools the exit fluid, and the diluent/coolant becomes part of the remediation fluid. Where the pollutants are combustible, the reactor is a combustor, and the diluent is water, which adds to the steam, which is generated by the combustion process. | 01-29-2009 |
20090064653 | PARTIAL LOAD COMBUSTION CYCLES - The part load method controls delivery of diluent fluid, fuel fluid, and oxidant fluid in thermodynamic cycles using diluent, to increase the Turbine Inlet Temperature (TIT) and thermal efficiency in part load operation above that obtained by relevant art part load operation of Brayton cycles, fogged Brayton cycles, or cycles operating with some steam delivery, or with maximum steam delivery. The part load method may control the TIT at the design level by controlling one or both of liquid and/or gaseous fluid water over a range from full load to less than 45% load. This extends operation to lower operating loads while providing higher efficiencies and lower operating costs using water, steam and/or CO2 as diluents, than in simple cycle operation. | 03-12-2009 |
20090071166 | THERMODYNAMIC CYCLES USING THERMAL DILUENT - A thermodynamic system that produces mechanical, electrical power, and/or fluid streams for heating or cooling. The cycle contains a combustion system that produces an energetic fluid by combustion of a fuel with an oxidant. A thermal diluent may be used in the cycle to improve performance, including but not limited to power, efficiency, economics, emissions, dynamic and off-peak load performance, and/or turbine inlet temperature (TIT) regulation and cooling heated components. The cycle preferably includes a heat recovery system and a condenser or other means to recover and recycle heat and the thermal diluent from the energetic fluid to improve the cycle thermodynamic efficiency and reduce energy conversion costs. The cycle may also include controls for temperatures, pressures, and flow rates throughout the cycle, and controls power output, efficiency, and energetic fluid composition. | 03-19-2009 |
20090071648 | HEAVY OIL RECOVERY WITH FLUID WATER AND CARBON DIOXIDE - Diluted wet combustion forms a hot process fluid or VASTgas comprising carbon dioxide (CO | 03-19-2009 |
20090180939 | TRIFLUID REACTOR - A thermally diluted exothermic reactor system is comprised of numerous orifices distributed within a combustor by distributed perforated contactor tubes or ducts. The perforated contactors deliver and mix diluent fluid and one or more reactant fluids with an oxidant fluid. Numerous micro-jets about the perforated tubes deliver, mix and control the composition of reactant fluid, oxidant fluid and diluent fluid. The reactor controls one or more of composition profiles, composition ratio profiles and temperature profiles in one or more of the axial direction and one or two transverse directions, reduces temperature gradients and improves power, efficiency and emissions. | 07-16-2009 |
20100276148 | HOT FLUID RECOVERY OF HEAVY OIL WITH STEAM AND CARBON DIOXIDE - Combustion gases with relatively high levels of carbon dioxide (CO | 11-04-2010 |
20120298215 | WET COMPRESSION APPARATUS AND METHOD - This wet compression invention with a vaporizable fluid mist demonstrates major performance improvements over the relevant art in achieving a high degree of saturation, providing sensible cooling, strongly reducing the temperature increase due to compression work, reducing excess diluent air flow for downstream combustion, reducing compression noise, and increasing the achievable compressor pressure ratio. These improvements are obtained by one or more of: high mist or overspray from a) progressive axial injection of vaporizable fluid along the streamwise compression flow path, and b) transverse vaporizable fluid delivery from stators, rotors, perforated tubes, and/or duct walls, matching the gaseous fluid flow distribution across the compressor stream; c) reducing the compressor cross-sectional flow area of downstream compressor stages relative to up-stream stages, and d) increasing the rate of downstream vaporizable fluid injection relative to the rate of upstream injection, as a function of each compressor stage pressure ratio. | 11-29-2012 |
20130062269 | BENDABLE STRAIN RELIEF FLUID FILTER LINER, METHOD AND APPARATUS - A method of forming a bendable slotted liner with multiple circumferentially overlapping non-axial keystone slots comprising: transversely profiling a rod to form a profiled rod, having bending members outwardly profiled wider than intermediate and inward widths, interspersed with bases profiled to bondably mate with axially adjacent bases on a neighboring winding; forming the profiled rod into alternating port and starboard bending members and base pairs, by one of, bonding transverse spacers to the rod, transversely corrugating the rod, and forming the rod with one of transverse outdents and indents; winding the profiled rod to the outer diameter; and bonding axially paired bases together; wherein configuring the non-axial slot circumferential length greater than the circumferential base length on adjacent rod windings, forming non-axial keystone slots between bending members providing axial strain relief, with outer slot widths within a prescribed slot range and axial strain relief capacity greater than 0.1%. | 03-14-2013 |
20130266902 | LOW EMISSIONS COMBUSTION APPARATUS AND METHOD - Clean combustion and equilibration equipment and methods are provided to progressively deliver, combust and equilibrate mixture of fuel, oxidant and aqueous diluent in a plurality of combustion regions and in one or more equilibration regions to further progress oxidation of products of incomplete combustion, in a manner that sustains combustion while controlling temperatures and residence times sufficiently to reduce CO and NOx emissions to below 25 ppmvd, and preferably to below 3 ppmvd at 15% O | 10-10-2013 |
Patent application number | Description | Published |
20080309573 | Modular digital UHF/VHF antenna - The invention relates to Radio Frequency (RF) antennas suitable for receiving and/or transmitting digital signals in the Ultra High Frequency (UHF) and/or Very High Frequency (VHF) ranges. The invention comprises a modular driven DUV antenna comprising a driven DUV element, an RF signal line RF communicatively connected to the driven DUV element, and an antenna mount supporting the DUV element; and a modular RF signal enhancer, supported by the antenna mount and selected from: an RF amplifier and a passive RF enhancer positioned to enhance the RF performance of the DUV antenna and comprising one of: an RF director, an RF reflector, and an RF booster. | 12-18-2008 |
20090283632 | Aircraft Attitude Control Configuration - An aircraft attitude control configuration enables control surfaces to provide attitude control for an aircraft at hover or low air speed conditions. The aircraft attitude control configuration includes a plurality of thrusters mounted to an aircraft for thrusting air, a first control surface kinematically coupled to the aircraft at a position downstream of a first thruster to enable a first vector force to be generated by a portion of the thrusted air from the first thruster on the first control surface, and a second control surface kinematically coupled to the aircraft at a position downstream of a second thruster, the first and the second control surfaces being displaced symmetrically on opposite sides of a longitudinal axis of the aircraft, the second control surface being configured to be independently and differentially movable with respect to the first control surface to enable a second vector force to be generated by a portion of the thrusted air from the second thruster on the second control surface. | 11-19-2009 |
20120145834 | Aircraft Attitude Control Configuration - Control surfaces in an aircraft attitude control configuration provide attitude control for an aircraft at hover or low air speed conditions. The aircraft attitude control configuration includes thrusters mounted to an aircraft, a first control surface kinematically coupled to the aircraft downstream of a first thruster to enable a first vector force to be generated by a portion of thrusted air from the first thruster on the first control surface, and a second control surface kinematically coupled to the aircraft of a second thruster. The control surfaces are displaced symmetrically a longitudinal axis of the aircraft. The control surfaces are independently and differentially movable with respect to each other to enable generation of a second vector force by a portion of thrusted air from the second thruster on the second control surface. | 06-14-2012 |
20150129208 | CALCINER ENHANCED OIL RECOVERY - A method of supplying crushed alkaline carbonate from a carbonate resource to a first calcining site having a design calcining capacity; calcining the crushed carbonate within a prescribed carbon dioxide (CO2) delivery distance from a first enhancement location within a first hydrocarbon resource, whereby generating CO2 with a local CO2 generating capacity and an alkaline oxide; forming a first enhancing fluid comprising generated CO2 and delivering it into the first enhancement site having an injector well weighted first enhancement location, whereby mobilizing hydrocarbon in the first enhancement site; producing a produced fluid comprising mobilized hydrocarbon and enhancing fluid; recovering liquid hydrocarbon from the produced fluid; wherein the prescribed CO2 delivery distance is less than 67% of a remote CO2 delivery distance, to the first enhancement location from a remote calcining site having an equal or greater design calcined CO2 generating capacity. Then calcining CO2 to enhance a second larger site. | 05-14-2015 |
Patent application number | Description | Published |
20080249031 | CRYSTALLINE FORMS - The present invention relates to crystalline forms of (3S)-3-[N—(N′-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-oxopentanoic acid (see formula I). The invention further relates to pharmaceutical compositions comprising such crystalline forms and to the use of said pharmaceutical compositions and said crystalline forms in the treatment of various conditions, particularly in the treatment of liver fibrosis. | 10-09-2008 |
20110053997 | Salts and Crystal Forms - The present invention relates to novel salts of the compound (R)-5-(2-Aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione, polymorphs of the salts and methods of their preparation. | 03-03-2011 |
20120046442 | ROMIDEPSIN SOLID FORMS AND USES THEREOF - The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I. | 02-23-2012 |
20120190817 | ROMIDEPSIN SOLID FORMS AND USES THEREOF - The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I. | 07-26-2012 |
20140256637 | ROMIDEPSIN SOLID FORMS AND USES THEREOF - The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I. | 09-11-2014 |
20140336132 | ROMIDEPSIN SOLID FORMS AND USES THEREOF - The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I. | 11-13-2014 |
20150218225 | ROMIDEPSIN SOLID FORMS AND USES THEREOF - The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I. | 08-06-2015 |
Patent application number | Description | Published |
20080221018 | Crystalline solid and amorphous forms of (-)- halofenate and methods related thereto - The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate. | 09-11-2008 |
20090326245 | Novel Polymorphs of Azabicyclohexane - The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms. | 12-31-2009 |
20110275695 | CRYSTALLINE FORMS OF ZOTEPINE HYDROCHLORIDE - The invention relates to crystalline forms of zotepine hydrochloride, including the crystalline hydrochloride salt of zotepine and two cocrystals of zotepine hydrochloride with benzoic acid. The preparation and characterization of these crystalline forms of zotepine hydrochloride is described. The invention also relates to the therapeutic use of the crystalline forms of zotepine hydrochloride to treat central nervous system disorders and to pharmaceutical compositions containing them. | 11-10-2011 |
20110294847 | Novel Polymorphs Of Azabicyclohexane - The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms. | 12-01-2011 |
20120136038 | Novel Polymorphs Of Azabicyclohexane - The invention provides polymorphic crystalline forms of acid addition salts of (±)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms. | 05-31-2012 |
20120232303 | Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto - The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate. | 09-13-2012 |
20130345279 | NOVEL POLYMORPHS OF AZABICYCLOHEXANE - The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms. | 12-26-2013 |
20140024852 | Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto - The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate. | 01-23-2014 |
20150225333 | Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto - The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate. | 08-13-2015 |